Bris­tol My­ers, Charles Riv­er join Se­ries A fund­ing for iVex­Sol

Mass­a­chu­setts-based iVex­Sol has se­cured fund­ing to the tune of $23.8 mil­lion in its lat­est Se­ries A round. The new in­vestors in­clude Bris­tol My­ers Squibb, man­u­fac­tur­er Charles Riv­er Lab­o­ra­to­ries and Asahi Ka­sei Med­ical.

iVex­Sol is a man­u­fac­tur­er of lentivi­ral vec­tors (LVV), used in mak­ing gene ther­a­pies, and this lat­est round of fundrais­ing brings its to­tal Se­ries A to­tal over $39 mil­lion, which will be used to re­cruit more em­ploy­ees and bol­ster its tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER